Daxor

Daxor EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Daxor (DXR) as of Oct 17, 2026 is -110.87. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 2,632.34 — a change of -104.21% (lower).

EV/OCF

-110.87

YoY

-104.21%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Daxor is 2025 -110.87 . EV/OCF (Enterprise Value to Operating Cash Flow) of Daxor was 2024 2,632.34 . It decreases by -104.21% lower compared to the previous year.

The Daxor EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-54.24 USD
Jan 1, 2019
21.93 USD
Jan 1, 2020
-27.15 USD
Jan 1, 2021
-25.09 USD
Jan 1, 2022
-88.56 USD
Jan 1, 2023
-18.51 USD
Jan 1, 2024
2,632.34 USD
Jan 1, 2025
-110.87 USD
The Daxor EV/OCF history
YEAREV/OCFYoY
-110.87-104.21%
2,632.34-14,321.08%
-18.51-79.10%
-88.56+253.02%
-25.09-7.60%
-27.15-223.81%
21.93-140.43%
-54.24-9.34%
-59.82-241.12%
42.39+1,050.02%
3.69-101.23%
-298.53—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Daxor Stock analysis

What does Daxor do? Daxor Corp, listed on the ticker DXR with ISIN US2394671034, is a health care company based in New York City, United States. The company went public on July 25, 1983. Daxor Corp develops and manufactures the BVA-100 blood volume analyzer, a diagnostic instrument cleared by the U.S. Food and Drug Administration (FDA). This device measures human blood volume and provides objective quantification of blood volume status and composition relative to patient-specific norms. The company reports that over 65,000 tests have been conducted at hospital centers across the United States. These tests are associated with improvements in hospital performance metrics for various surgical and medical conditions, including reductions in mortality and readmissions for heart failure and critical care patients. Daxor Corp is engaged in advancing healthcare through blood volume analysis, focusing on optimal fluid management. The company is conducting ongoing clinical trials related to heart failure treatment, supported by the National Institutes of Health (NIH), and is also under contract to develop additional analyzers. The company's website is https://www.daxor.com/. Daxor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Daxor stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Daxor is -110.87 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Daxor changed from 2,632.34 to -110.87, representing a -104.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Daxor since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Daxor with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Daxor

All Key Metrics — Daxor